LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) is investigating potential claims on behalf of investors of Roche Holding AG (“Roche” or the “Company”) (Other OTC: RHHBY) concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the Roche investigation page on our website at http://www.glancylaw.com/case/roche-holding-ag.
On June 5, 2017, several media outlets reported that a new study has allegedly shown that adding Roche's breast cancer drug Perjeta to the Company's older treatment Herceptin, displayed only small benefits while augmenting the one-year cost of treatment by a significant amount. Additionally, it was shown that the combination of both Perjeta and Herceptin brought about an increase of certain side effects, including severe diarrhea, more than just Herceptin alone.
On this news, Roche fell over 5%, or $1.76 per share, to close at $32.61 per share on June 5, 2017.
If you purchased Roche securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to this potential class action, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to email@example.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.